4/A//SEC Filing
PHASE4 VENTURES III LP 4/A
Accession 0001140361-18-005596
CIK 0001322505other
Filed
Feb 6, 7:00 PM ET
Accepted
Feb 7, 4:35 PM ET
Size
12.9 KB
Accession
0001140361-18-005596
Insider Transaction Report
Form 4/AAmended
Transactions
- Sale
Common Stock
2018-01-30$37.06/sh−1,500$55,588→ 1,065,447 total(indirect: Held by Phase4 Ventures III GP LP) - Sale
Common Stock
2018-01-30$34.40/sh−98,500$3,388,459→ 1,066,947 total(indirect: Held by Phase4 Ventures III GP LP)
PHASE4 VENTURES III GP LP
10% Owner
Transactions
- Sale
Common Stock
2018-01-30$34.40/sh−98,500$3,388,459→ 1,066,947 total(indirect: Held by Phase4 Ventures III GP LP) - Sale
Common Stock
2018-01-30$37.06/sh−1,500$55,588→ 1,065,447 total(indirect: Held by Phase4 Ventures III GP LP)
PHASE4 VENTURES III LP
10% Owner
Transactions
- Sale
Common Stock
2018-01-30$34.40/sh−98,500$3,388,459→ 1,066,947 total(indirect: Held by Phase4 Ventures III GP LP) - Sale
Common Stock
2018-01-30$37.06/sh−1,500$55,588→ 1,065,447 total(indirect: Held by Phase4 Ventures III GP LP)
Phase4 Partners Ltd
10% Owner
Transactions
- Sale
Common Stock
2018-01-30$34.40/sh−98,500$3,388,459→ 1,066,947 total(indirect: Held by Phase4 Ventures III GP LP) - Sale
Common Stock
2018-01-30$37.06/sh−1,500$55,588→ 1,065,447 total(indirect: Held by Phase4 Ventures III GP LP)
Footnotes (4)
- [F1]The number of securities reported represents an aggregate number of shares sold in multiple market transactions over a range of sale prices. The Reporting Persons undertake to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Persons at each separate price within the range.
- [F2]Sale prices range from $34.40 to $34.71, inclusive.
- [F3]Sale prices range from $36.60 to $37.43, inclusive.
- [F4]Consists of shares held by Phase4 Ventures III GP LP ("Phase4 GPLP") in its capacity as general partner of Phase4 Ventures III LP ("Phase4 III"). Phase4 GPLP is the general partner of Phase4 III. The general partner of Phase4 GPLP is Phase 4 Ventures III General Partner Limited ("Phase4 GP"). Phase4 GP has appointed Phase4 Partners Limited ("Phase4 Partners") to act as the manager of Phase4 III. Dr. Alastair McKinnon, Denise Scots-Knight, PhD, and Charles Sermon are Directors of Phase4 Partners (the "Phase4 Directors"). Each of the Phase4 Directors, Phase4 Partners, Phase4 GP, Phase 4 GPLP and Phase4 III may be deemed to beneficially own the shares held by Phase4 GPLP in its capacity as general partner of Phase4 III, but disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any.
Documents
Issuer
ALBIREO PHARMA, INC.
CIK 0001322505
Entity typeother
Related Parties
1- filerCIK 0001687344
Filing Metadata
- Form type
- 4/A
- Filed
- Feb 6, 7:00 PM ET
- Accepted
- Feb 7, 4:35 PM ET
- Size
- 12.9 KB